Drugs and Polymers for Delivery Systems in OA Joints: Clinical Needs and Opportunities

Polymers

Maarten Janssen²  George Mihov¹  Tim Welting²  Jens Thies¹ 

[1] DSM Biomedical, Koestraat 1, 6167 RA Geleen, the Netherlands; E-Mails:;Department of Orthopaedic Surgery, Maastricht University Medical Center, P. Debyelaan 25, 6229 HX Maastricht, the Netherlands; E-Mails:

关键词: osteoarthritis;    drug delivery systems;    DMOAD;   

DOI  :  10.3390/polym6030799

来源: mdpi

【 摘 要 】

Osteoarthritis (OA) is a big burden of disease worldwide and one of the most common causes of disability in the adult population. Currently applied therapies consist of physical therapy, oral medication, intra-articular injections, and surgical interventions, with the main goal being to reduce pain and improve function and quality of life. Intra-articular (IA) administration of drugs has potential benefits in OA treatment because it minimizes systemic bioavailability and side effects associated with oral administration of drugs without compromising the therapeutic effect in the joint. However, IA drug residence time is short and there is a clinical need for a vehicle that is able to provide a sustained release long enough for IA therapy to fulfill its promise. This review summarizes the use of different polymeric systems and the incorporated drugs for IA drug delivery in the osteoarthritic joint with a primary focus on clinical needs and opportunities.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.